Literature DB >> 22037882

Clinical trial design in brain metastasis: approaches for a unique patient population.

David M Peereboom1.   

Abstract

Clinical trials in brain metastases present challenges and opportunities unique to this patient population. With the increase in awareness and screening for brain metastases, smaller and often asymptomatic lesions are detected, creating the opportunity for trials of pre-irradiation chemotherapy. The goal of earlier intervention is advanced by studies to prevent brain metastases in high-risk populations. Sequencing of systemic chemotherapy with experimental chemotherapy in the context of a clinical trial requires collaboration between the investigators and the treating medical oncologists beginning ideally during design of the study. Adaptive randomization improves the efficiency of randomized trials in the brain metastasis population. Finally, collaborative efforts between patients and physicians with the support from patient advocacy groups will help advance the quality and the clinical trial options for patients with brain metastases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22037882     DOI: 10.1007/s11912-011-0204-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  37 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

Authors:  Ulla Wilking; Eva Karlsson; Lambert Skoog; Thomas Hatschek; Elisabet Lidbrink; Goran Elmberger; Hemming Johansson; Linda Lindström; Jonas Bergh
Journal:  Breast Cancer Res Treat       Date:  2010-07-14       Impact factor: 4.872

3.  Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.

Authors:  Noël E C Schartz; Cécile Farges; Isabelle Madelaine; Heriberto Bruzzoni; Fabien Calvo; Axel Hoos; Céleste Lebbé
Journal:  Melanoma Res       Date:  2010-06       Impact factor: 3.599

Review 4.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

Authors:  B Glimelius; M Lahn
Journal:  Ann Oncol       Date:  2011-01-13       Impact factor: 32.976

5.  A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.

Authors:  Rachel A Freedman; Elizabeth Bullitt; Lixian Sun; Rebecca Gelman; Gordon Harris; Jennifer A Ligibel; Ian E Krop; Ann H Partridge; Emily Eisenberg; Eric P Winer; Nancy U Lin
Journal:  Clin Breast Cancer       Date:  2011-06-22       Impact factor: 3.225

6.  Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.

Authors:  Jens Hoffmann; Iduna Fichtner; Margit Lemm; Philip Lienau; Holger Hess-Stumpp; Andrea Rotgeri; Birte Hofmann; Ulrich Klar
Journal:  Neuro Oncol       Date:  2008-09-09       Impact factor: 12.300

7.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

Review 8.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Chemotherapy induces regression of brain metastases in breast carcinoma.

Authors:  D Rosner; T Nemoto; W W Lane
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

10.  Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study.

Authors:  Y Ushio; N Arita; T Hayakawa; H Mogami; H Hasegawa; S Bitoh; Y Oku; H Ikeda; N Kanai; M Kanoh
Journal:  Neurosurgery       Date:  1991-02       Impact factor: 4.654

View more
  2 in total

Review 1.  Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.

Authors:  Alexandra S Zimmer; Patricia S Steeg
Journal:  J Mol Med (Berl)       Date:  2014-11-22       Impact factor: 4.599

2.  Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial.

Authors:  Wenyin Shi; Yaacov Richard Lawrence; Hak Choy; Maria Werner-Wasik; David W Andrews; James J Evans; Kevin D Judy; Christopher J Farrell; Yaron Moshel; Adam C Berger; Voichita Bar-Ad; Adam P Dicker
Journal:  J Neurooncol       Date:  2014-04-13       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.